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Characterizing the Blood Oxygen 
Level-Dependent Fluctuations in 
Musculoskeletal Tumours Using 
Functional Magnetic Resonance 
Imaging
Li-Sha Duan1,2,*, Meng-Jun Wang1,2,*, Feng Sun1,2, Zhen-Jiang Zhao1,2, Mei Xing1,2,  
Yu-Feng Zang3,4, Steven Louis5, Sheng-Jie Cui6, Jian-Ling Cui1,2 & Han Zhang3,4,7
This study characterized the blood oxygen level-dependent (BOLD) fluctuations in benign and 
malignant musculoskeletal tumours via power spectrum analyses in pre-established low-frequency 
bands. BOLD MRI and T1-weighted imaging (T1WI) were collected for 52 patients with musculoskeletal 
tumours. Three ROIs were drawn on the T1WI image in the tumours’ central regions, peripheral regions 
and neighbouring tissue. The power spectrum of the BOLD within each ROI was calculated and divided 
into the following four frequency bands: 0.01–0.027 Hz, 0.027–0.073 Hz, 0.073–0.198 Hz, and 0.198–
0.25 Hz. ANOVA was conducted for each frequency band with the following two factors: the location 
of the region of interest (LoR, three levels: tumour “centre”, “peripheral” and “healthy tissue”) and 
tumour characteristic (TC, two levels: “malignant” and “benign”). There was a significant main effect 
of LoR in the frequencies of 0.073–0.198 Hz and 0.198–0.25 Hz. These data were further processed 
with post-hoc pair-wise comparisons. BOLD fluctuations at 0.073–0.198 Hz were stronger in the 
peripheral than central regions of the malignant tumours; however, no such difference was observed 
for the benign tumours. Our findings provide evidence that the BOLD signal fluctuates with spatial 
heterogeneity in malignant musculoskeletal tumours at the frequency band of 0.073–0.198 Hz.
Acute hypoxia (i.e., transient cycles of hypoxia–reoxygenation) is known to occur in solid tumours1 and may be 
associated with resistance to radiation therapy2,3, impaired delivery of chemotherapeutic agents4 or metastasis 
development5. The origin of acute hypoxia is not firmly established; however, it is generally believed to result 
from tumour blood flow instabilities. Flow fluctuations may result from arteriolar vasomotion6,7, haemodynamic 
changes resulting from a disorganized vascular hierarchy8, and other factors.
Several methods can detect acute hypoxia. Oxygen microelectrodes9,10 and fibre-optic oxygen-sensing 
device11,12 can invasively detect the spontaneous oxygen tension fluctuations in animal tumour models by insert-
ing a microprobe into the tumour. In addition to their invasive nature, another drawback of these techniques is 
the restriction of spatial resolution. Additionally, although phosphorescence lifetime imaging to detect the partial 
oxygen tension through a cutaneous window chamber has high spatial resolution, it is an invasive method and 
is not allowed in humans13. Additionally, hypoxia can be detected using positron emission tomography (PET) 
with a hypoxia-specific radio-tracer. Acute hypoxia may be identified through acute changes in the intensity 
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of the tracer in human tumours with a mathematical model14. However, detection of acute hypoxia using PET 
requires several injections of radiotracers over days. Moreover, in intratumoural injections of perfluorocarbon 
(PFC) compounds, the relaxation rate 1/T1 is proportional to the percentage of O2 acquired. This is also an inva-
sive procedure and has limited temporal resolution15.
Blood oxygen level-dependent (BOLD) functional MRI that depends on deoxyhaemoglobin as an endogenous 
contrast agent is sensitive to changes in blood flow and deoxyhaemoglobin content with high temporal and spatial 
resolution16–18. The spatial and temporal heterogeneity of spontaneous T2* (BOLD) MR signal fluctuations was 
first observed in an implanted fibrosarcoma mouse model by Baudelet et al.19,20 and later confirmed in tumour 
xenograft models of colorectal carcinoma by Goncalves and colleagues21.
However, the occurrence of spontaneous BOLD signal fluctuations in the tumours described above has never 
been demonstrated in human tumours. We examined patients with malignant or benign musculoskeletal (MSK) 
tumours using BOLD for 6 minutes per patient and analysed the BOLD fluctuation characteristic in the centre 
and periphery of each tumour via power spectrum analyses. The aim of this study was to assess the spatial hetero-
geneity of the BOLD signal fluctuations in human MSK tumours via power spectrum analyses in pre-established 
low-frequency bands.
Results
Participants and Histopathology. Of the 52 MSK tumour patients, four had excessive body motions 
(translation > 3 mm or rotation > 3°) that could have introduced severe artefacts in BOLD signals; these patients 
were removed from further analyses. The data from the remaining 48 patients were entered into further analyses 
(Table 1). Histological results showed that 35 patients had malignant tumours; the others13 had benign tumours. 
The malignant MSK tumours included osteosarcoma (12 cases), malignant fibrous histiocytoma4, synovial 
sarcoma3, two cases each with alveolar sarcoma, Ewing sarcoma, liposarcoma, metastatic renal clear cell carcinoma 
and chondrosarcoma, and one case each with metastatic adenocarcinoma, primitive neuroectodermal tumour, 
malignant chondroblastoma, epidermoid leiomyosarcoma, fibrosarcoma and malignant tenosynovial giant cell 
tumour. The benign MSK tumours consisted of giant cell tumours of bone in 10 cases and one case each with 
neurofibroma, lipoma and fibromatosis.
Variability in BOLD Fluctuations Within and Around MSK tumours. There was a difference in 
BOLD fluctuations (measured according to the averaged normalized power in each frequency band) between 
various locations within and around the MSK tumour tissue. Images derived from a voxel-wise calculation of 
the BOLD fluctuation magnitude for various frequency bands from a randomly selected patient are shown in 
Fig. 1. As can be observed, there is a visible variability in the BOLD fluctuation power of BOLD signal within and 
around this malignant MSK tumour.
Statistical Analyses. The power spectrum of the BOLD fMRI signal was divided into the following four 
frequency bands according to a previous study22: band-1, 0.01–0.027 Hz; band-2, 0.027–0.073 Hz; band-3, 0.073–
0.198 Hz; and band-4, 0.198–0.25 Hz. The reason for adopting these cut-offs is that the BOLD fluctuation power 
within the four bands was approximately equal22. These results are statistically shown in our 2-by-3 ANOVA 
Variables (malignant)a Values Variables (benign)b Values
Cases 35 Cases 13
Age (yrs) Age (yrs)
Mean ± sd 35.74 ± 17.97 Mean ± sd 41.62 ± 16.18
Range 14–75 Range 18–70
Males-no. (%) 24 (68.60) Males-no. (%) 7 (53.80)
Position-no. (%) Position-no. (%)
Femur 13 (37.14) Femur 4 (30.77)
Tibia 6 (17.14) Tibia 5 (38.46)
Fibula 2 (5.71) Fibula 1 (7.70)
Humerus 2 (5.71) Humerus n.s.
Sacrum 1 (2.86) Sacrum n.s.
Os Innominatum 1 (2.86) Os Innominatum n.s.
Calcaneus 1 (2.86) Calcaneus n.s.
Soft tissue 9 (25.71) Soft tissue 3 (23.08)
Tumour volume *(cm3) Tumour volume *(cm3)
Mean ± sd 163.02 ± 140.88 Mean ± sd 159.13 ± 180.96
Range 23.40–546.60 Range 19.60–588.60
Table 1. Demographic and Tumour Information of 48 Cases. aOsteosarcoma, malignant fibrous 
histiocytoma, synovial sarcoma, alveolar sarcoma, Ewing sarcoma, liposarcoma, chondrosarcoma, metastatic 
adenocarcinoma, metastatic renal clear cell carcinoma, primitive neuroectodermal tumour, malignant 
chondroblastoma, epidermoid leiomyosarcoma, fibrosarcoma, malignant tenosynovial giant cell tumour. bGiant 
cell tumour of bone, neurofibroma, lipoma, fibromatosis. yrs = years; no. = number. *Selected 37 tumours to 
calculate their volumes using the formula (4/3) π abc (a, b, c = the 3 radii).
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analysis, which used tumour characteristic (TC, consisting of two levels: “malignant” and “benign”) and the loca-
tion of ROI (LoR, consisting of three levels: tumour “centre/c” and “peripheral/p”, and “healthy tissue”) as two 
factors. As shown in Table 2, there was no significant main effect for the TC or the interaction effect between TC 
and LoR in all frequency bands. Notably, Table 2 also showed a significant main effect for LoR in the frequency of 
band-3 (0.073–0.198 Hz) (P = 0.0167) and band-4 (0.198–0.25 Hz) (P = 0.0243).
After the ANOVA analyses, the data with a significant main effect of LoR was further processed with post-hoc 
pair-wise comparison, as shown in Table 3. For malignant tumours, there was a statistically significant difference 
(P < 0.05, corrected) in BOLD fluctuation power in band-3 and a trend towards a significant difference (P < 0.1, 
corrected) in band-4 between the tumour periphery and the centre (i.e., p > c); the benign tumours showed no 
such difference (Fig. 2).
Intra- and Inter-rater Reliability in ROI definition. To determine whether these results were affected 
by the ROI selection, the intra- and inter-rater reliability of the BOLD fluctuation power between ROI selections 
Figure 1. BOLD fluctuation magnitude within and around a malignant MSK tumour from a randomly 
selected patient. The first row shows the 3DT1-weighted image of the MSK tumour in the femur and the 
BOLD-fMRI field-of-view (within the red rectangle). The second to the last row shows the BOLD fluctuation 
magnitude (normalized power) within frequency bands 1–4, which were rendered onto the T1-weighted image.
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were calculated. The intra-rater value ICC for the two measurements performed by the primary radiologist 
(M.J.W) were 0.67 ± 0.13 (range: 0.49–0.93), which means that the reliability of the ROI definition is fair to 
excellent (Table 4). The inter-rater ICC values between the ROI definitions of radiologists M.J.W and Z.J.Z also 
indicated that the reliability is fair to excellent, which were 0.62 ± 0.15 (range: 0.37–0.81, between Z.J.Z’s meas-
urement and M.J.W’s first measurement) and 0.71 ± 0.11 (range: 0.54–0.87, between Z.J.Z’s measurement and 
M.J.W’s second measurement)(Table 4).
Discussion
This is the first time that human MSK tumours have been characterized using a frequency spectrum analysis 
of BOLD in specific frequency bands. Taking our observations together, ANOVA showed that in the frequency 
bands 0.073–0.198 Hz (band-3, P = 0.0167) and 0.198–0.25 Hz (band-4, P = 0.0243), there was a significant dif-
ference in the BOLD fluctuation power between the centre and the periphery of the MSK tumour and the sur-
rounding normal muscle (Table 2). The post-hoc simple effect analysis showed that only in the malignant tumour 
were there significantly (band-3, P < 0.05, corrected) or a trend towards significantly (band-4, P < 0.1, corrected) 
higher BOLD fluctuations in the peripheral tumour region than the central tumour region; there was no such 
difference for benign MSK tumours (Table 3).
According to Ogawa’s group, the source of BOLD fMRI signal displays the ratio of oxyhaemoglobin and 
deoxygenated haemoglobin in the arterioles, capillaries and post-capillary venules23. The BOLD signal has also 
been shown to be positively related to blood flow or the partial pressure of oxygen in normal tissue or tumour 
tissue20,24. Flow fluctuation is also called flowmotion. Flowmotion as detected via perfusion imaging is closely 
associated with the BOLD fluctuation25,26. Blood flow fluctuation may induce acute hypoxia in tumours. Thus, 
spontaneous BOLD fluctuations are likely related to acute hypoxia in tumours18–21.
The BOLD fluctuations in band-3 in the periphery of the malignant MSK tumours were larger than those in 
the centre in our series, whereas for benign tumours there was no significant difference in all frequency bands 
between the centre and periphery. Häfner detected the perfusion of human cutaneous malignant melanomas, 
benign melanocytic nevi and normal skin27. The wavelet analysis reveals that the mean vasomotion scale variance 
values obtained from healthy skin significantly differed from the margins and centres of cutaneous malignant 
melanomas but did not significantly differ between the margin and centre of benign melanocytic nevi. These 
findings support our results. However, the amplitude difference of BOLD fluctuation between the centre and 
periphery in malignant MSK tumours was only at the band of 0.073–0.198 Hz; the cause for this remains to be 
determined.
Freq band (Hz) SS MS F value** P value
Main effect of LoR
Band-1: 0.01–0.027 4516.10 2258.06 2.73 0.0714
Band-2: 0.027–0.073 2487.50 1243.77 2.92 0.0596
Band-3: 0.073–0.198 4971.00 2485.51 4.30 0.0167*
Band-4: 0.198–0.25 41110.30 20555.10 3.89 0.0243*
Main effect of TC
Band-1: 0.01–0.027 461.60 461.58 0.26 0.6117
Band-2: 0.027–0.073 501.70 501.69 0.68 0.4145
Band-3: 0.073–0.198 0.40 0.39 0 0.9846
Band-4: 0.198–0.25 2959.20 2959.20 0.26 0.6156
Interaction effect of LoR and TC
Band-1: 0.01–0.027 1527.20 763.59 0.92 0.4018
Band-2: 0.027–0.073 9.90 4.94 0.01 0.9885
Band-3: 0.073–0.198 291.00 145.51 0.25 0.7780
Band-4: 0.198–0.25 4607.50 2303.80 0.44 0.6481
Table 2.  The ANOVA Table of Power Difference in 48 Cases. Note: *P value lower than 0.05; **The degree 
of freedom is F(2,82) in the main effect of the location of the ROI, F(1,46) in the main effect of the tissue 
characteristic, and F(2,82) in the interaction effect of LoR and TC. SS = sum of the square; MS = mean square. 
LoR = location of ROI; TC = tissue characteristic.
Tumour
Frequency 
band (Hz)
Centre of 
tumour (c)
Periphery of 
tumour (p)
Normal 
muscle (m)
P value 
(p > c)
P value 
(p > m)
P value 
(c > m)
Malignant
0.073–0.198 20.46 ± 22.46 33.86 ± 32.16 16.88 ± 12.14 0.0049** n.s. n.s.
0.198–0.25 61.38 ± 89.21 95.69 ± 110.20 38.85 ± 24.66 0.0127* n.s. n.s.
Benign
0.073–0.198 16.91 ± 10.89 32.62 ± 50.81 21.71 ± 23.19 n.s. n.s. n.s.
0.198–0.25 41.20 ± 33.07 75.69 ± 125.20 44.32 ± 70.63 n.s. n.s. n.s.
Table 3.  Post-hoc pairwise comparisons analysis with Sidak adjustment in 0.073–0.198 Hz and 0.198–0.25 Hz. 
Note: **P value lower than 0.05 after correction, which is a P value less than 0.0085. *P value lower than 0.1 after 
correction, which is a P value less than 0.0174. p > c: power of the periphery is higher than that of the centre. p > m: 
power of the periphery is higher than that of the normal muscle.
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Interestingly, the frequency band of 0.073–0.198 Hz in tumours has been suggested to be caused primarily by 
vascular myogenic activity in vasomotion28,29. Further study is needed to determine whether this frequency band 
detected via BOLD has the same implications.
The frequency of oxygen fluctuation (hypoxia-reoxygenation) detected via microprobe9,11,12 or 19F MRI methods9 
ranges widely from 0.00035–0.0167 Hz, with an average of approximately 0.001 Hz.
Our MR scanning protocol precluded the analysis of frequency bands higher than 0.25 Hz (due to the limited 
temporal sampling rate, 2 s) and less than 0.00278 Hz (due to the 6-minute signal acquisition time). To elucidate 
the spatial heterogeneity of the amplitude of the BOLD signal at some fluctuation frequenceses, we tested the 
differences between the benign and malignant MSK tumours as well as between the centre and periphery of the 
MSK tumours. Only an amplitude of 0.073–0.198 Hz was significantly higher for the peripheral tumour region 
in the malignant tumour. The significant frequency band (0.073–0.198 Hz) detected in our study may provide 
new pathological and physiological significance in characterizing the acute hypoxia fluctuations in the tumours.
Figure 2. Post-hoc pairwise comparison analysis with Sidak adjustment in 2 frequency bands between 
benign and malignant tumours. **P < 0.05 after correction; *P < 0.1 after correction.
Frequency band (Hz)
ROIs in the centre 
of the tumour
ROIs in the periphery 
of the tumour
ROIs in the 
normal muscle
Band-1: 0.01–0.027 
0.62a 0.68 0.80
0.72b/0.59c 0.37/0.54 0.79/0.86
Band-2: 0.027–0.073 
0.64 0.60 0.65
0.80/0.71 0.59/0.64 0.45/0.66
Band-3: 0.073–0.198 
0.81 0.49 0.58
0.70/0.75 0.52/0.63 0.43/0.78
Band-4: 0.198–0.25
0.93 0.52 0.68
0.81/0.83 0.63/0.64 0.66/0.87
Table 4.  Values of Intra-(M.J.W-1 and M.J.W-2) or Inter-(M.J.W-1–Z.J.Z/M.J.W-2–Z.J.Z) Rater Correlation 
Coefficient for the Reproducibility Analyses. Note: a = ICC values between M.J.W-1 and M.J.W-2; b = ICC 
values between M.J.W-1 and Z.J.Z; c = ICC values between M.J.W-2 and Z.J.Z.
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In the present study, 48 patients with malignant or benign MSK tumours were studied; this represents a rel-
atively small sample size. The substantially smaller sample size of benign tumours compared with malignant 
tumours may induce statistical bias.
In conclusion, we found that in the frequency band of 0.073–0.198 Hz, the fMRI BOLD fluctuation power of 
the central is lower than the peripheral regions in human malignant MSK tumours; however, no significant differ-
ence was found for benign tumours. The meaning of this difference remains under investigation.
Materials and Methods
Participants. Fifty-two patients (34 males and 18 females; age 39.9 ± 17.8 years, 14–75 years) who were hos-
pitalized consecutively from February 2009 to June 2011 with primary MSK tumours were included in this study. 
All patients were drug-naive and without any treatment prior to MR imaging. The demographic and clinical 
information are summarized in Table 1. The inclusion criteria were the following: (1) the tumour had to be pre-
dominately solid; (2) the tumour dimension had to be larger than 3 cm in each of the axial, sagittal and coronal 
plains to facilitate ROI drawing; and (3) the tumour had no extensive intra tumour necrosis or bleeding. Tumour 
characteristics were determined via histological testing after resection or needle biopsy. This study was approved 
by the institutional research ethics board in the Third Hospital of Hebei Medical University, China. All exper-
iments were performed in accordance with relevant guidelines and regulations, and all patients signed written 
informed consent before the study was carried out.
MR Imaging. MR imaging was performed on a 1.5 T Siemens MR scanning system (Avanto, Siemens, 
Erlangen, Germany). Scanning was performed with patients lying in a supine position and being asked 
to relax throughout the scan. Depending on which body part had tumours and was scanned, image acquisi-
tion used one of the following coils: a large circularly polarized flexible coil, an eight-channel knee coil or an 
eight-channel body array coil. The scanning protocol included three-dimensional turbo fast low angled shot 
(FLASH) T1-weighted images (3D T1WI) (repetition time/echo time, 1900/2.97 ms; flip angle, 15°; number 
of slices, 176; slice thickness/gap, 1/0.5 mm; acquisition matrix, 256 × 246; field of view, 220 mm × 220 mm). 
Two-dimensional echo planar imaging (EPI) BOLD fMRI with 20 axial slices was also taken (repetition time/
echo time, 2000/40 ms; slice thickness/gap, 5/1 mm; field of view, 220 mm × 220 mm; acquisition matrix, 64 × 64; 
voxel size, 3.44 mm × 3.44 mm × 6.0 mm; number of dummy scans, 3; scanning time, 6 min, 177 frames total). 
3DT1WI images were taken to identify the tumour locations; the BOLD fMRI scan was taken to detect BOLD 
fluctuations in corresponding body tissues.
Data Preprocessing. The fMRI data were preprocessed using DPARSFA v2.430 and REST v1.831 based on 
SPM8 (www.fil.ion.ucl.ac.uk/spm) and Matlab 2010a (MathWorks, Inc., Natick, MA, USA). See Fig. 3 for a flow-
chart of the entire analysis procedure. The preprocessing steps included the following: (1) the fMRI data were con-
verted to Neuroimaging Informatics Technology Initiative (NIfTI) format; (2) the first five frames of each patient’s 
fMRI data were discarded to allow for MR machine equilibrium and the patients’ adaption; (3) within-frame slice 
acquisition timing was corrected; (4) patient’s body motion was corrected using a 6-parameter rigid-body trans-
formation, and the patients found to have excessive body motion (> 3 mm or > 3 degrees) were excluded from 
further analyses; (5) the three-dimensional T1 image of each patient was co-registered to the patient’s own aver-
aged BOLD fMRI image to spatially match the two modalities. Note that we did not perform spatial re-sampling 
or smoothing because we intended to keep the original BOLD signal and to minimize spatial blurring influence 
and signal contamination caused by neighbouring voxels.
ROI Drawing. BOLD fMRI images provide critical information about blood flow and oxygen levels but do 
not readily allow visual distinction between tumour and non-tumour regions due to the limited spatial resolution. 
Therefore, we defined ROIs based on 3D T1WI and then transformed the coordinates of the ROIs to match the 
BOLD fMRI images according to the projection derived from the co-registration. Prior to ROI definition, the 
tumour tissue was divided into three nearly concentric regions (centre, transition and periphery regions) from 
the tumour centre to periphery as equally as possible by an experienced radiologist (M.J.W) according to pre-
vious studies32. As the transition area within a tumour was difficult to be differentiated from the tumour centre 
and peripheral regions29, we intended not to use it as an ROI. Within tumours, ROIs were only chosen from the 
tumour centre and periphery. The normal muscle surrounding the tumour but without abnormal signal was also 
defined as one ROI type. Therefore nine ROIs, three in the centre (c), three in the periphery (p) of the tumour 
and three in the surrounding normal muscle (m), with a radius of 4 mm each, were chosen for each patient. The 
three ROIs belonging to the same tissue type (c, p, or m) were chosen to spread as far as possible32 from each other 
to avoid systemic noise contamination. The regions with necrosis, calcification or that included large arteries or 
veins were avoided when defining the ROIs. For ten patients, the fMRI data did not include adequate normal 
muscle tissue because of the limited imaging field of view; we did not define the ROIs of the normal muscle for 
these patient (i.e., the muscle ROIs were available for 38 of 48 patients). Each ROI contained five voxels of the 
BOLD fMRI.
Power Spectrum Analyses. For each patient, averaged BOLD time series across the five voxels in each ROI 
were calculated, and a linear trend was removed from them. The averaged BOLD signal for each ROI was trans-
formed from the temporal to frequency domain with a fast Fourier transformation using Matlab (i.e., frequency 
power spectrum in which the “power” is the square of the BOLD fluctuation amplitude, Fig. 1). This power 
spectrum was then divided into the following four frequency bands according to a previous study17: band-1, 
0.01–0.027 Hz; band-2, 0.027–0.073 Hz; band-3, 0.073–0.198 Hz; and band-4, 0.198–0.25 Hz. The power values 
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for each ROI were then normalized by dividing the total power value of the entire frequency band (0–0.25 Hz) 
to facilitate inter-patient comparisons (similar to the calculation of fractional amplitude of low-frequency fluc-
tuation in Zang et al.33). The normalized power values for the three ROIs belonging to the same tissue type were 
further averaged for each frequency band for the Analysis of Variance (ANOVA).
Statistical Analyses. We investigated whether there was significant difference in BOLD fluctuation power 
between different locations of ROIs or between malignant and benign tumours. Specifically, there were two main 
factors in the ANOVA model as follows: (1) tumour characteristics (TC), which consisted of two levels (i.e., either 
benign or malignant tumour) and (2) the location of the ROI (LoR), which has three levels ((i.e., the tumour 
centre (c), the tumour periphery (p), and the normal muscle (m)). The 2 × 3 mixed-designed ANOVA (the two 
fixed effect factors stated above and one random effect factor, “subject”) was performed on the averaged BOLD 
fluctuation power values on each frequency band. Two main effects (i.e., the TC and LoR main effects) and one 
interaction effect (i.e., TC-by-LoR) were assessed. For any significant (P < 0.05, uncorrected) main effect derived 
from the ANOVA in any frequency band, simple effect analyses using post-hoc pair-wise comparisons were con-
ducted to further explore the direction of the difference in BOLD fluctuation power. The significance level was set 
to P < 0.05 and corrected for multiple comparisons with Sidak adjustment.
Intra-Rater and Inter-Rater Reliability Assessment. We chose relatively objective ROI selection cri-
teria (described above) to reduce the introduction of errors due to human subjectivity. To assess the intra-rater 
reliability of our ROI selection criteria, we performed the ROI definition twice with our primary radiologist 
(M.J.W.). The first and second round of ROI definition were separated by one week according to the same criteria 
but fully independent from each other. To determine inter-rater reliability, all of the ROIs were also independently 
drawn by a second experienced radiologist (Z.J.Z.) who was blinded to all previous results. The averaged BOLD 
fluctuation power value for each tissue type for each patient was calculated and fed into intra-class correlation 
coefficients (ICC) calculation. We calculated the intra-rater and inter-rater ICCs for each of the frequency bands. 
All ICC values were evaluated with the criterion reported in Zhang et al.34. An ICC value larger than 0.75 indi-
cates “excellent” reliability, between 0.59–0.75 indicates “good”, 0.40–0.58 indicates “fair”, and below 0.40 indicates 
“poor” reliability.
Figure 3. Schematic illustration of the course to data processing and analysis. The selected patient is a 
19-year-old man with osteosarcoma in his left femur. (a) Functional image. (b) 3D T1-weighted image  
(c) A ROI in the centre of the tumour with a 4-mm radius. Its centre coordinate is (97,114,132). (d) Time course 
after preprocessing. (e) Power spectrum using FFT. ROI = region of interest; FFT = fast Fourier transformation; 
ANOVA = analysis of variance.
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